FDA — authorised 3 December 1975
- Marketing authorisation holder: HOSPIRA
- Status: approved
🇺🇸 Clinimix E 2.75/5 Sulfite Free W/ Elect In Dextrose 5% W/ Calcium In Plastic Container in United States
FDA authorised Clinimix E 2.75/5 Sulfite Free W/ Elect In Dextrose 5% W/ Calcium In Plastic Container on 3 December 1975
Marketing authorisations
FDA — authorised 26 November 2019
- Application: NDA212832
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA — authorised 26 July 2024
- Application: NDA218343
- Marketing authorisation holder: AMNEAL
- Local brand name: POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
Clinimix E 2.75/5 Sulfite Free W/ Elect In Dextrose 5% W/ Calcium In Plastic Container in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Nephrology approved in United States
Frequently asked questions
Is Clinimix E 2.75/5 Sulfite Free W/ Elect In Dextrose 5% W/ Calcium In Plastic Container approved in United States?
Yes. FDA authorised it on 3 December 1975; FDA authorised it on 26 November 2019; FDA authorised it on 26 July 2024.
Who is the marketing authorisation holder for Clinimix E 2.75/5 Sulfite Free W/ Elect In Dextrose 5% W/ Calcium In Plastic Container in United States?
HOSPIRA holds the US marketing authorisation.